Clinical Trial Update: Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating sirolimus and maraviroc on CCR5 expression and HIV-1 reservoir in HIV-infected kidney transplant recipients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Kidney Transplant

Drugs mentioned

• Maraviroc (maraviroc)
• Sirolimus (Sirolimus)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Hiv, Kidney Transplant | Phase 4 | Status: WITHDRAWN